www.aerami.com Open in urlscan Pro
3.124.221.80  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to main content Skip to footer
 * Home
 * About
 * Inhalation Technology
 * Pipeline
 * News & Media
   * Press Releases
   * In The News
   * Email Alerts
 * Contact


OPENING NEW PATHWAYS FOR CARDIOPULMONARY AND CARDIOMETABOLIC DISEASE PATIENTS


VIA PRECISION INHALED DRUG DELIVERY

At Aerami Therapeutics, we leverage our proprietary inhalation technology to
develop differentiated inhaled therapies for the treatment of cardiopulmonary
and cardiometabolic conditions.


AER-901

INHALED IMATINIB FOR PULMONARY ARTERIAL HYPERTENSION

A drug-device combination product candidate in Phase 1 for the treatment of
pulmonary arterial hypertension


AER-601

INHALED GLP-1 FOR TYPE 2 DIABETES

An inhaled glucagon-like peptide-1 (GLP-1) analog for the treatment of
post-prandial hyperglycemia associated with Type 2 diabetes


AER-501

HUMAN INHALED INSULIN FOR TYPE 1 AND 2 DIABETES

A soft mist inhaled human insulin to improve glycemic control in Type 1 and Type
2 diabetes


COMMITMENT THAT’S EASY TO TAKE IN

Aerami Therapeutics is a clinical stage biopharmaceutical company engaged in the
development of differentiated inhaled therapies for the treatment of
cardiopulmonary and cardiometabolic conditions.

About Our Company


LATEST NEWS

Jun 16, 2022


AERAMI THERAPEUTICS APPOINTS LISA YAÑEZ AS CHIEF OPERATING OFFICER

View Press Release View all news
Nov 18, 2021


AERAMI THERAPEUTICS APPOINTS BARRY DEUTSCH AS CHIEF FINANCIAL OFFICER

Read Press Release
Nov 11, 2021


AERAMI THERAPEUTICS APPOINTS DARLENE DEPTULA-HICKS TO ITS BOARD OF DIRECTORS

Read Press Release
View all news


EMAIL ALERTS

Sign up today and receive company updates straight to your inbox.

Sign up today
 * 
 * 

©2022 Aerami Therapeutics Holdings, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap

We use cookies to offer you a better browsing experience, including personalized
advertising. By continuing to use the site you agree to their use.

Privacy Policy

Ok